immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. this proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. we then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.
Company profile
Ticker
IMNM
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
770694340
IMNM stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
3 Apr 24
S-3ASR
Automatic shelf registration
3 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
28 Mar 24
8-K
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
26 Mar 24
8-K
Other Events
14 Feb 24
424B5
Prospectus supplement for primary offering
14 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
Results of Operations and Financial Condition
13 Feb 24
S-3ASR
Automatic shelf registration
13 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 90.74 mm | 90.74 mm | 90.74 mm | 90.74 mm | 90.74 mm | 90.74 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.54 mm | 1.89 mm | 2.87 mm | (no burn) |
Cash used (since last report) | n/a | n/a | 10.28 mm | 12.58 mm | 19.12 mm | n/a |
Cash remaining | n/a | n/a | 80.46 mm | 78.17 mm | 71.62 mm | n/a |
Runway (months of cash) | n/a | n/a | 52.1 | 41.4 | 24.9 | n/a |
Institutional ownership, Q2 2023
8.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 8 |
Closed positions | 0 |
Increased positions | 10 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 12.03 bn |
Total shares | 5.27 mm |
Total puts | 29.90 k |
Total calls | 32.64 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
MorphImmune | 2.66 mm | $20.48 mm |
Longboat Family Office | 660.48 k | $9.40 mm |
Point72 Asset Management | 418.13 k | $3.31 bn |
Vanguard | 373.88 k | $2.96 bn |
Alpine Global Management | 365.97 k | $2.90 mm |
Prentice Capital Management | 112.13 k | $886.96 mm |
BMO Bank of Montreal | 100.33 k | $799.66 mm |
Geode Capital Management | 81.21 k | $642.39 mm |
Cerity Partners | 67.13 k | $530.97 mm |
Millennium Management | 66.01 k | $522.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Kinney Horn | Stock option Common Stock | Grant | Acquire A | No | No | 23 | 300,000 | 6.90 mm | 300,000 |
31 Jan 24 | Sandra G. Stoneman | Stock option Common Stock | Grant | Acquire A | No | No | 16.57 | 200,000 | 3.31 mm | 200,000 |
31 Jan 24 | Max Rosett | Stock option Common Stock | Grant | Acquire A | No | No | 16.57 | 175,000 | 2.90 mm | 175,000 |
News
Guggenheim Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $35
15 Apr 24
Wedbush Maintains Outperform on Immunome, Raises Price Target to $33
1 Apr 24
Immunome Q4 Adj EPS $(0.15) Beats $(0.28) Estimate, Sales $3.83M Beat $2.07M Estimate
28 Mar 24
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
28 Mar 24
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
22 Mar 24
Press releases
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
5 Apr 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
26 Mar 24
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
26 Mar 24
Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies
18 Mar 24
Immunome to Participate in the Leerink Partners Global Biopharma Conference
7 Mar 24